Novo Nordisk | NVO - Trade Debtors


Novo Nordisk reported DKK14.27B in Trade Debtors for its fiscal quarter ending in June of 2025.





Trade Debtors Change Date
ANI Pharmaceuticals USD 255.43M 25.65M Mar/2026
Aurora Cannabis CAD 48.26M 1.53M Dec/2025
Bausch Health Companies USD 2.19B 160M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Canopy Growth CAD 140.42M 113.56M Dec/2025
Corcept Therapeutics USD 39.07M 20.71M Mar/2026
Drreddys Laboratories INR 1.41B 11.6M Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
GlaxoSmithKline GBP 7.94B 178M Mar/2026
Merck USD 11.78B 345M Dec/2025
Nektar Therapeutics USD 1.78M 1.12M Dec/2025
Novartis USD 9.6B 2.69B Mar/2026
Novo Nordisk DKK 106.26B 11.21B Mar/2026
Novo Nordisk DKK 14.27B 72.1B Jun/2025
Pacira USD 125.64M 1.57M Mar/2026
Perrigo USD 697.1M 84.3M Mar/2026
Phibro Animal Health USD 215.87M 2.02M Dec/2025
Prestige Brands USD 191.92M 1.46M Mar/2026
Sanofi EUR 482M 85M Mar/2026
Supernus Pharmaceuticals USD 182.18M 5.62M Mar/2026
Zoetis USD 1.51B 84M Mar/2026